EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

De novo urothelial carcinoma in kidney transplant recipients: a single-center retrospective cohort study

Jacob Schmidt, Malte Lehnert, Isabel Lichy, Irena Goranova, Sarah Weinberger, Jonathan Jeutner, Lukas Kurz, Henning Plage, Thorsten Schlomm, Frank Friedersdorff, Robert Peters, Nadine Biernath und 1 weitere

International Urology and Nephrology · 2026

DOI: 10.1007/s11255-026-05026-2 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift International Urology and Nephrology, 2026. Verfasst von Jacob Schmidt und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Charité - Universitaetsmedizin Berlin, Freie Universitaet Berlin, Humboldt-Universitaet Zu Berlin, Berlin Institute of Health,…. Hauptthemen laut MEDLINE: Kidney Transplantation, Carcinoma, Transitional Cell, Postoperative Complications, Urologic Neoplasms. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Charité - Universitätsmedizin Berlin.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

To characterize the incidence, clinicopathologic features, treatment patterns, and both oncologic and graft-related outcomes of de novo urothelial carcinoma (UC) in kidney transplant recipients (KTRs) at a large German transplant center.

Methods

Retrospective single-center cohort of KTRs (2005–2024). 19 patients with post-transplant UC were identified among 4,012 KTRs. We extracted demographics, transplant and tumor characteristics, treatments, graft outcomes, and survival. The standardized incidence ratio (SIR) was calculated using population-based incidence rates, and Kaplan–Meier estimates were used for overall survival (OS), metastasis-free survival (MFS), and graft survival (GS).

Results

UC occurred in 0.47% of KTRs, yielding an SIR of 2.21 (95% confidence interval [CI] 1.33–3.44) compared with the general population. Most tumors were bladder-based (63.2%), but there was a high proportion of upper-tract urothelial carcinoma (UTUC; 31.6%), including graft-involving tumors. Radical surgery was performed in 47.4% of patients, 15.8% received systemic chemotherapy, and intra-vesical therapy was rarely used. Median OS after UC diagnosis was 55 months, with estimated 3- and 5-year OS rates of 70% and 51%, respectively, and 3- and 5-year MFS rates of 73%. Graft failure occurred in 47.4% of patients, and in 21.1% of the total cohort it was directly attributed to UC.

Conclusion

Post-transplant UC in KTRs is associated with a more than twofold increased incidence compared with the general population and a disproportionate burden of upper tract and graft-involving tumors. Management must carefully balance oncologic control against preservation of transplant function in a setting where standard intra-vesical and systemic therapies are constrained by immunosuppression. These findings support risk-adapted lifelong urologic surveillance and highlight the need for dedicated treatment strategies tailored to immunosuppressed patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Kidney TransplantationCarcinoma, Transitional CellPostoperative ComplicationsUrologic NeoplasmsHumansRetrospective StudiesFemaleMaleMiddle AgedIncidenceGraft SurvivalAgedAdult

Stichwörter der Autor:innen

Cancer incidenceKidney transplant recipientsKidney transplantationPost-transplant malignancyUpper-tract urothelial carcinomaUrothelial carcinoma

Autor:innen und Institutionen

  • Department of Urology, Charité - Universitaetsmedizin Berlin, Freie Universitaet Berlin, Humboldt-Universitaet Zu Berlin, Berlin Institute of Health, Augustenburger Platz 1, 13353, Berlin, Germany.
  • Department of Urology, Evangelisches Krankenhaus Königin Elisabeth Herzberge, Berlin, Germany.
  • Department of Urology, Charité - Universitaetsmedizin Berlin, Freie Universitaet Berlin, Humboldt-Universitaet Zu Berlin, Berlin Institute of Health, Augustenburger Platz 1, 13353, Berlin, Germany. Bernhard.ralla@charit…

Förderung

  • Charité - Universitätsmedizin Berlin

Zitieren

APA

Schmidt, J., Lehnert, M., Lichy, I., Goranova, I., Weinberger, S., Jeutner, J., Kurz, L., Plage, H., Schlomm, T., Friedersdorff, F., Peters, R., Biernath, N., & Ralla, B. (2026). De novo urothelial carcinoma in kidney transplant recipients: a single-center retrospective cohort study. International Urology and Nephrology. https://doi.org/10.1007/s11255-026-05026-2

Vancouver

Schmidt J, Lehnert M, Lichy I, Goranova I, Weinberger S, Jeutner J, et al. De novo urothelial carcinoma in kidney transplant recipients: a single-center retrospective cohort study. International Urology and Nephrology. 2026. doi:10.1007/s11255-026-05026-2

BibTeX
@article{Schmidt2026,
  author = {Schmidt, Jacob and Lehnert, Malte and Lichy, Isabel and Goranova, Irena and Weinberger, Sarah and Jeutner, Jonathan and Kurz, Lukas and Plage, Henning and Schlomm, Thorsten and Friedersdorff, Frank and Peters, Robert and Biernath, Nadine and Ralla, Bernhard},
  title = {De novo urothelial carcinoma in kidney transplant recipients: a single-center retrospective cohort study},
  journal = {International Urology and Nephrology},
  year = {2026},
  doi = {10.1007/s11255-026-05026-2}
}
Kostenlos starten →